Cell-type specific impact of metformin on monocyte epigenetic age reversal in virally suppressed older people living with HIV.

ABSTRACT: The anti-diabetic drug metformin may promote healthy aging. However, few clinical trials of metformin assessing biomarkers of aging have been completed. In this communication, we retrospectively examined the effect of metformin on epigenetic age using principal component (PC)-based epigenetic clocks, mitotic clocks, and pace of aging in peripheral monocytes and CD8⁺ T cells from participants in two clinical trials of virologically-suppressed people living with HIV (PLWH) with normal glucose receiving metformin. In a small 24-week clinical trial that randomized participants to receive either adjunctive metformin or observation, we observed significantly decreased PCPhenoAge and PCGrimAge estimates of monocytes from only participants in the metformin arm by a mean decrease of 3.53

SUBMITTER: Corley MJ 

PROVIDER: S-EPMC10776116 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature